免疫检查点抑制剂相关心肌病的诊疗研究进展  

Research advances in diagnosis and treatment of cardiomyopathy associated with immune checkpoint inhibitors

作　　者：罗丹 谭梦琴 张舟 王福军 LUO Dan;TAN Mengqin;ZHANG Zhou;WANG Fujun(Department of Cardiology,Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital,Jishou Hunan 416000;Emergency Medical Center,Hunan University of Medicine General Hospital,Huaihua Hunan 418000;Cardiac Center,Geriatric Hospital of Hainan,Haikou Hainan 571100,China)

机构地区：[1]湘西土家族苗族自治州人民医院心内科,湖南吉首416000 [2]湖南医药学院总医院急救医学中心,湖南怀化418000 [3]海南省老年病医院心脏中心,海南海口571100

出　　处：《实用心电学杂志》2024年第6期557-562,共6页Journal of Practical Electrocardiology

基　　金：湖南省卫生健康委员会科研资助项目(202203014682);中国药文化研究会医药科教分会科研一般项目(2024KXJS0004)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)显著提高了肿瘤患者的存活率,但越来越多的免疫相关心血管不良事件严重影响到患者的治疗和预后。本文综述了ICIs相关心肌病的发病机制、临床表现、诊断和治疗等方面的最新研究进展,以供心血管及肿瘤科医生在临床实践中借鉴。Immune checkpoint inhibitors(ICIs) have shown remarkable success in increasing tumor patients' survival rates,but the increasing immune-related adverse cardiovascular events seriously affect the treatment and prognosis of these patients.This review summarizes the latest research advances in the pathogenesis,clinical manifestations,diagnosis and treatment of ICIs-related cardiomyopathy in order to provide references for both cardiologists and oncologists in clinical practice.

关 键 词：心脏毒性 免疫检查点抑制剂 心肌病 应激性心肌病 

分 类 号：R542.2[医药卫生—心血管疾病]